What is JPMA?

Japan Pharmaceutical Manufacturers Association (JPMA) is a voluntary association of 68 R&D-oriented pharmaceutical companies (as of January 1, 2026). In recent years, the diversity of medical needs and the need for life science products have been increasing.

In recent years, drug discovery has become an even more complex and sophisticated endeavor due to the diversification of medical needs and the acceleration of technological innovation in the life science field. In response to these changes, JPMA is building and strengthening the drug discovery ecosystem through collaboration between industry, academia, and government. At the same time, we are also focusing on resolving issues common to the pharmaceutical industry and promoting public understanding of pharmaceuticals. These activities are led by committees and professional organizations whose members transcend the boundaries of member companies, and are used to make policy and institutional proposals and deepen dialogue with society.

Internationally, as one of the major pharmaceutical associations along with the Pharmaceutical Research and Manufacturers of America (PhRMA) and theEuropean Federation of Pharmaceutical Industries and Associations (EFPIA), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH ) is working to develop international rules as a founding industry member, and through its leadership of the Asian Pharmaceutical Associations Council (APAC) is also contributing to improving access to medicines in Asia, APAC has also contributed to improving access to medicines in the Asian region. Furthermore, as a member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), ICH is addressing issues related to global health, such as improving access to medicines, protecting intellectual property, combating infectious diseases, and promoting the SDGs.

We will continue to further deepen our cooperation with related organizations and diverse stakeholders in Japan and abroad in order to enhance transparency and credibility of the Japanese pharmaceutical industry as a whole and to ensure its continued sound development. Through "co-creation," in which we create value together with the public, including patients, we will promote innovation and contribute to improving the health and quality of life (QOL) of people around the world.

JPMA Guide

Related Information

TOP